subscribeSubscribe
FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
PRESS RELEASE
31 Aug 2022
Share Share
Enhertu strikes again with a PhIII success in another breast cancer population

Enhertu strikes again with a PhIII success in another breast cancer population
Kyle LaHucik ENDPTS
16 Aug 2022
Share Share
Natco Pharma Ltd`s Generic Lapatinib Ditosylate Receives Approval In US

Natco Pharma Ltd`s Generic Lapatinib Ditosylate Receives Approval In US
FDA
29 Sep 2020
Share Share
No change to product information for breast cancer medicine Tyverb

No change to product information for breast cancer medicine Tyverb
EMA
27 Mar 2020
Share Share
Puma Biotech cancer launch Nerlynx suffered in Q1.

Puma Biotech cancer launch Nerlynx suffered in Q1.
Angus Liu FIERCE PHARMA
10 May 2019
Share Share
Re-analysis of data on use of breast cancer, Tyverb treatment with trastuzumab

Re-analysis of data on use of breast cancer, Tyverb treatment with trastuzumab
EMA
30 Apr 2019
Share Share
Hetero launches Generic Lapatinib in India

Hetero launches Generic Lapatinib in India
BIOSPECTRUM
15 Jan 2019
Share Share
Puma Biotech Announces Top Line Results of Phase III NALA Trial of Neratinib

Puma Biotech Announces Top Line Results of Phase III NALA Trial of Neratinib
BUSINESSWIRE
18 Dec 2018
Share Share
ASLAN posts positive top-line varlitinib phase 2 data in breast cancer

ASLAN posts positive top-line varlitinib phase 2 data in breast cancer
Angus Liu FIERCE PHARMA
16 Feb 2017
Share Share
Pfizer’s First-in-class Breast Cancer Therapy Wins EU Licensing

Pfizer’s First-in-class Breast Cancer Therapy Wins EU Licensing
R Clifford PMLIVE
11 Nov 2016
Share Share